Celgene Knocks Feds' Support Of $40B Off-Label FCA Suit
The federal government's statement supporting a whistleblower's $40 billion False Claims Act suit against Celgene Corp. over the off-label promotion of cancer drugs Thalomid and Revlimid doesn't dismantle the company's arguments...To view the full article, register now.
Already a subscriber? Click here to view full article